More on Eli Lilly (LLY -1.7%) Q3: net profit +7% to $1.33B, boosted by payment from former...


More on Eli Lilly (LLY -1.7%) Q3: net profit +7% to $1.33B, boosted by payment from former partner Amylin. Sales breakdown: antidepressant Cymbalta +16% to $1.24B, cancer drug Alimta +2% to $643.6M. Antipsychotic Zyprexa -68% to $374.5M, due to patent loss; animal-health products +6% to $479.4M. Reiterates 2012 guidance.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs